Premium
Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia
Author(s) -
BarzilaiBirenboim Shlomit,
AradCohen Nira,
Nirel Ronit,
Avrahami Galia,
Harlev Dan,
Gilad Gil,
Elhasid Ronit,
Izraeli Shai,
Litichever Naomi,
Elitzur Sarah
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15752
Subject(s) - medicine , thrombophilia , venous thromboembolism , factor v leiden , pediatrics , anticoagulant , thrombosis , venous thrombosis
Summary This study investigated the prevalence of inherited thrombophilia, risk of venous thromboembolism ( VTE ) and benefit of low molecular weight heparin prophylaxis in 476 Israeli children with acute lymphoblastic leukaemia ( ALL ) treated between 2004 and 2016. Thrombophilia was found in 15·5%. Arab children had a higher prevalence of F5 R506Q (factor V Leiden) than Jewish children (19·4% vs. 2·9%, P < 0·01). Patients with thrombophilia had higher VTE rates VTE (26·5% vs. 5·6%, P < 0·001). None of the thrombophilic children given prophylaxis had severe VTE . Routine evaluation for inherited thrombophilia followed by thromboprophylaxis when findings are positive may benefit at‐risk patients with ALL .